| Sep 4 |
SpringWorks Therapeutics Inc (SWTX) CEO Saqib Islam Sells 49,000 Shares
|
| Aug 28 |
FDA accepts SpringWorks' application for mirdametinib for NF1-PN
|
| Aug 28 |
FDA Grants Priority Review to SpringWorks Therapeutics’ New Drug Application for Mirdametinib for the Treatment of Adults and Children with NF1-PN
|
| Aug 23 |
High Growth Tech Stocks to Watch in August 2024
|
| Aug 14 |
Druckenmiller's Duquesne pares Apple, Coupang, adds Adobe, TeraWulf, others
|
| Aug 9 |
SpringWorks Therapeutics Recent Developments Move This To Speculative Buy (Upgrade)
|
| Aug 9 |
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Just Reported Second-Quarter Earnings And Analysts Are Lifting Their Estimates
|
| Aug 8 |
SpringWorks Q2 Earnings Beat, Ogsiveo Drives Revenues
|
| Aug 8 |
SpringWorks Therapeutics, Inc. (NASDAQ:SWTX): Is Breakeven Near?
|
| Aug 7 |
SpringWorks Therapeutics: Rising On A Strong Post-Launch Quarter, Now Justified As A Buy
|
